Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Helman

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|January 10, 2009
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor ISung-Hyeok Hong, Joseph Briggs, Rachel Newman, et al.
The American Journal of Surgical Pathology|January 4, 2013
Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutationMarkku Miettinen, Jonathan Keith Killian, Zeng-Feng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomasElizabeth Fox, Brigitte C Widemann, Douglas S Hawkins, et al.
Cancer Research|September 17, 2005
Expression profiles of osteosarcoma that can predict response to chemotherapyTsz-Kwong Man, Murali Chintagumpala, Jaya Visvanathan, et al.
Plos One|May 30, 2013
Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]Lorna Kelly, Kenneth Bryan, Su Young Kim, et al.
Nature Reviews. Cancer|January 26, 2007
Compressing drug development timelines in oncology using phase '0' trialsShivaani Kummar, Robert Kinders, Larry Rubinstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Cediranib for metastatic alveolar soft part sarcomaShivaani Kummar, Deborah Allen, Anne Monks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal TumorJohn Glod, Fernanda I Arnaldez, Lori Wiener, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Cancer Research|January 2, 2009
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitorsFei Huang, Ann Greer, Warren Hurlburt, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|January 10, 2009
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor ISung-Hyeok Hong, Joseph Briggs, Rachel Newman, et al.
The American Journal of Surgical Pathology|January 4, 2013
Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutationMarkku Miettinen, Jonathan Keith Killian, Zeng-Feng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomasElizabeth Fox, Brigitte C Widemann, Douglas S Hawkins, et al.
Cancer Research|September 17, 2005
Expression profiles of osteosarcoma that can predict response to chemotherapyTsz-Kwong Man, Murali Chintagumpala, Jaya Visvanathan, et al.
Plos One|May 30, 2013
Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]Lorna Kelly, Kenneth Bryan, Su Young Kim, et al.
Nature Reviews. Cancer|January 26, 2007
Compressing drug development timelines in oncology using phase '0' trialsShivaani Kummar, Robert Kinders, Larry Rubinstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Cediranib for metastatic alveolar soft part sarcomaShivaani Kummar, Deborah Allen, Anne Monks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal TumorJohn Glod, Fernanda I Arnaldez, Lori Wiener, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Cancer Research|January 2, 2009
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitorsFei Huang, Ann Greer, Warren Hurlburt, et al.
Pageof 4